Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial

The topical phosphodiesterase 4 inhibitor roflumilast has been studied in several dermatologic conditions.

Source: Journal of the American Academy of Dermatology - January 20, 2024 Category: Dermatology Authors: Andrew Blauvelt, Zoe D. Draelos, Linda Stein Gold, Javier Alonso-Llamazares, Neal Bhatia, Janet DuBois, Seth B. Forman, Melinda Gooderham, Lawrence Green, Scott T. Guenthner, Adelaide A. Hebert, Edward Lain, Angela Y. Moore, Kim A. Papp, Matthew Zirwas, S Source Type: research